Viridian Therapeutics, Inc. (VRDN) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 13 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for VRDN is $43.10, representing a +183.7% upside from the current price of $15.19. Price targets range from a low of $34.00 to a high of $50.00.
